

DIABETES SECTOR GROUP

Working together across Europe for better diabetes care





Structure of this presentation



Why we are here

Diabetes is a global epidemic set to expand The way it is managed and treated requires new thinking



Who we are

MedTech Europe's Diabetes Sector group Our vision and purpose



We all face the same challenges

We have come a long way in treating diabetes, and have a long way to go Moving from fragmented healthcare systems towards a sustainable future



The solution will come from us all

Collaboration among all stakeholders is the key to tackle diabetes We are here to listen to you



Diabetes is global epidemic – it requires new thinking

Diabetes a **long term**, **chronic** and currently **incurable** disease, its prevalence is on the **rise**. More action must be taken at **every level** to avoid this global threat.

- 1 in 12 people live with diabetes, 387 million people worldwide
- In Europe, over 50 million people live with diabetes every day
- The number of lives affected by the disease increases greatly if you include friends, family, loved ones and carers.
- If current trends are not reversed, the WHO predicts a doubling of prevalence across the world by 2050
- To tackle a crisis of this scale, new technologies, new partnerships and new approaches to health service delivery will be required

Who are the European Diabetes Sector Group?

- As industry, we have a **commercial interest** in medtech.
- This Group's mission, as you will see, looks beyond this
- We represent the biggest **medical technology** producers in the world
- We are newly formed, with new vision and ambition
- We are **complementary to pharmaceuticals yet different**, think chemistry vs physics













Our vision and purpose



Our Group brings together Diabetes technology companies to **champion the objectives of patients and their associations** for the **best choices** to prevent, manage and ultimately cure diabetes

Our Group commits to:

- Actively raising awareness around diabetes prevention and diabetes care;
- Demonstrating the value that high-quality, safe and innovative devices bring through improving the quality of life of people living with diabetes and containing long-term costs of the diabetes pandemic;
- Partnering with external stakeholders, both public and private, to ensure that the most effective technologies are available across Europe;
- Being a **trusted partner** in the diabetes environment

We have come a long way... (1/2)





We have come a long way... (2/2)







...and have a long way to go

To achieve change, patients, HCPs, policy makers and industry must communicate and collaborate better



- Today, healthcare systems are fragmented.
- One of our concerns is, medtech are fundamentally different to medication, and this is not well understood



- Healthcare is increasingly global and interconnected
- The future and sustainability of healthcare, is in our capacity to ensure diabetes care is treated holistically

The first step for us is to listen, including you from the beginning



Our aim is to foster collaboration and cooperation with other **stakeholders** in the diabetes care setting to find ways to tackle this issue **together**, more **efficiently**

- What are your views of health systems as they stand?
- How do you view the way diabetes is tackled?
- What do you think the **future** of diabetes care should/will be?
- Which problems do you usually encounter in your work fighting diabetes and helping patients?
- Who is the most likely to help you?
- How could we, as an industry sector group, help you?

